View in EDS HTML Full Text PDF Full Text

Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.

Saved in:
Bibliographic Details
Title: Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.
Authors: Kramer, Kim1 (AUTHOR) kramerk@mskcc.org, Pandit-Taskar, Neeta2 (AUTHOR), Kushner, Brian H.1 (AUTHOR), Zanzonico, Pat3 (AUTHOR), Humm, John L.3 (AUTHOR), Tomlinson, Ursula1 (AUTHOR), Donzelli, Maria1 (AUTHOR), Wolden, Suzanne L.4 (AUTHOR), Haque, Sophia2 (AUTHOR), Dunkel, Ira1 (AUTHOR), Souweidane, Mark M.5 (AUTHOR), Greenfield, Jeffrey P.5 (AUTHOR), Tickoo, Satish6 (AUTHOR), Lewis, Jason S.2 (AUTHOR), Lyashchenko, Serge K.2 (AUTHOR), Carrasquillo, Jorge A.2 (AUTHOR), Chu, Bae3 (AUTHOR), Horan, Christopher3 (AUTHOR), Larson, Steven M.2 (AUTHOR), Cheung, Nai-Kong V.1 (AUTHOR)
Source: Journal of Hematology & Oncology. 11/12/2022, Vol. 15 Issue 1, p1-12. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17568722
DOI:10.1186/s13045-022-01383-4